89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...

In living organisms, protein molecules with different chemical structures called proteoforms, are produced from a single gene to perform a variety of physiological protein functions. It has been ...

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase III drugs for Liver Cirrhosis have a 44% phase transition success ...

In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Fibrosis. According to GlobalData, Phase III drugs for Fibrosis does not have sufficient historical data to build an ...

which has thus become one of the most important means we have for investigating molecular structure. There is, indeed, no experimental method that gives more detailed information on this subject.

Researchers have now uncovered the 3D structure of the RNA enzyme SAMURI. Their study provides insights into the development of ribozymes and the evolution of catalytically active RNA. Researchers ...

Alboslani detailed this research in her presentation "X-ray echoes from Sgr A* reveal the 3D structure of molecular clouds in the Galactic Center" at the 245th meeting of the American Astronomical ...

The company’s lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). According ...

The company's lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). According ...